📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Virinchi Ltd Subsidiary Stake Diluted to 51% Following •7.83 Cr Promoter Investment
Virinchi Limited's subsidiary, Virinchi Health Care Private Limited (VHPL), has allotted 52.22 lakh equity shares to promoter Viswanath Kompella for a total consideration of •7.83 crore. This transaction, executed via warrant conversion at •15 per share, has reduced Virinchi Limited's stake in the subsidiary from 100% to 51%. VHPL is a significant contributor to the group, accounting for 30.73% of the consolidated turnover in FY24-25. While the company remains a subsidiary, the substantial 49% minority interest now held by the promoter will impact future consolidated net profit attributable to shareholders.
Key Highlights
Promoter Viswanath Kompella acquired a 49% stake in VHPL for •7.83 crore
Virinchi Limited's ownership in the healthcare subsidiary diluted from 100% to 51%
VHPL contributed •92.54 crore (30.73%) to consolidated revenue in FY2024-25
The allotment was based on an independent enterprise valuation of •312.08 crore for VHPL
A total of 52,22,000 warrants were converted into equity shares as of March 9, 2026
💼 Action for Investors
Investors should assess if the •312 crore valuation for the healthcare business is fair and monitor how the 49% stake dilution affects the parent company's bottom line. The direct capital infusion into the subsidiary by the promoter may signal growth plans but also increases related-party involvement.
Virinchi Ltd Allots 13.15 Lakh Equity Shares to Promoter Group on Warrant Conversion
Virinchi Limited has successfully allotted 13,15,715 equity shares to Vivo Bio Tech Limited, a promoter group entity, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% application money, totaling approximately Rs. 2.76 crore, to complete the conversion. This move increases the total issued and subscribed share capital to Rs. 108.80 crore, representing 10,87,96,896 equity shares.
Key Highlights
Allotment of 13,15,715 equity shares to Promoter Group entity Vivo Bio Tech Limited
Issue price of Rs. 28 per share including a premium of Rs. 18 per share
Receipt of Rs. 2,76,30,015 representing the final 75% payment for warrant conversion
Total paid-up share capital increased to Rs. 108,79,68,960 divided into 10.88 crore shares
💼 Action for Investors
The conversion of warrants by a promoter group entity is a positive signal indicating long-term commitment and confidence in the company's prospects. Investors should monitor the utilization of the newly raised capital and its impact on the company's debt-to-equity ratio.
Virinchi Shareholders Approve Related Party Investment and Warrant Issue for Healthcare Subsidiary
Virinchi Limited shareholders have approved two major special resolutions through a postal ballot concluded on February 23, 2026. The resolutions facilitate investment by a related party into Virinchi Health Care Private Limited, a 100% subsidiary, and the issuance of convertible equity warrants by the same entity. Both proposals received strong support from public shareholders, with over 92% voting in favor. This move is expected to provide necessary capital for the healthcare division's operations or expansion.
Key Highlights
Approval for related party investment in 100% subsidiary Virinchi Health Care Private Limited
Issuance of convertible equity warrants by the healthcare subsidiary approved
Resolution 1 (Investment) passed with 92.7% majority representing 2,558,985 votes in favor
Resolution 2 (Warrants) passed with 92.61% majority representing 2,556,489 votes in favor
Promoters and promoter group abstained from voting as they were interested parties
💼 Action for Investors
Investors should monitor the specific terms and valuation of the investment and warrants to understand the impact on the subsidiary's ownership structure. This capital infusion could be a precursor to scaling the healthcare business.
Virinchi Ltd Allots 20.7 Lakh Equity Shares to Promoter Group at Rs 28 Per Share
Virinchi Limited has successfully allotted 20,70,000 equity shares to Vivo Bio Tech Limited, a member of the Promoter Group, following the conversion of warrants. The allotment was executed at an issue price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% of the application money, totaling approximately Rs. 4.35 crore, to complete the conversion. This move increases the company's total paid-up share capital to Rs. 107.48 crore, represented by over 10.74 crore shares.
Key Highlights
Allotment of 20,70,000 equity shares to Promoter Group entity Vivo Bio Tech Limited
Conversion price set at Rs. 28 per share, including a premium of Rs. 18 per share
Receipt of Rs. 4,34,70,000 representing the final 75% payment for the warrants
Total issued and subscribed share capital increased to 10,74,81,181 equity shares
The transaction demonstrates promoter commitment and provides a capital infusion of over Rs. 4.3 crore
💼 Action for Investors
Investors should view the promoter's decision to convert warrants as a positive sign of confidence in the company's future. However, one should also account for the minor equity dilution resulting from the increased share count.
Virinchi Q3 Results: Consolidated Profit Returns to ₹1.60 Cr; Standalone PAT Jumps 152% YoY
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, showing a 24.5% sequential recovery from Q2 but a 6.7% decline year-on-year. The company returned to a consolidated net profit of ₹1.60 crore, recovering from a massive ₹13.67 crore loss in the previous quarter. Standalone performance was notably stronger, with net profit rising 152% YoY to ₹8.38 crore. Despite the quarterly recovery, the company remains in a consolidated net loss of ₹11.70 crore for the nine-month period ending December 2025.
Key Highlights
Consolidated Revenue for Q3 FY26 at ₹76.89 crore, up 24.5% QoQ but down 6.7% YoY
Consolidated Net Profit of ₹1.60 crore vs a loss of ₹13.67 crore in Q2 FY26
Standalone Net Profit surged to ₹8.38 crore from ₹3.32 crore in the same quarter last year
SaaS Business (US Fintech) led segment performance with ₹40.20 crore revenue and ₹8.39 crore profit
Health Care Services contributed ₹25.55 crore to revenue with a segment profit of ₹3.13 crore
💼 Action for Investors
Investors should track the sustainability of the return to consolidated profitability and investigate the causes of the significant losses in subsidiaries that are dragging down consolidated performance relative to standalone results. The strong performance of the SaaS/Fintech segment remains the primary value driver for the company.
Virinchi Q3 FY26: Consolidated Revenue at ₹76.89 Cr, Returns to Profitability QoQ
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, marking a 24.5% recovery from the previous quarter. The company successfully returned to a consolidated net profit of ₹1.60 crore, reversing a heavy loss of ₹13.67 crore in Q2 FY26. Standalone performance was notably stronger, with net profit jumping 152% YoY to ₹8.38 crore, primarily driven by the SaaS and IT services segment. However, on a consolidated basis, both revenue and profit remain lower compared to the same quarter last year (Q3 FY25).
Key Highlights
Consolidated Revenue stood at ₹76.89 Cr, up 24.5% QoQ but down 6.7% YoY.
Returned to Consolidated Net Profit of ₹1.60 Cr vs a loss of ₹13.67 Cr in Q2 FY26.
Standalone Net Profit grew 152% YoY to ₹8.38 Cr from ₹3.32 Cr.
Consolidated Finance Costs remain high at ₹7.85 Cr for the quarter.
SaaS Business (US Fintech) remains the primary driver of standalone profitability, contributing ₹40.20 Cr to revenue.
💼 Action for Investors
Investors should monitor the sustainability of the turnaround in consolidated profitability and the performance of the healthcare subsidiary which appears to be dragging group margins. While the standalone IT business is robust, high consolidated finance costs remain a key risk factor to watch.
Virinchi Allots 17.14 Lakh Equity Shares to Promoter Group via Warrant Conversion
Virinchi Limited has allotted 17,14,285 equity shares to Vivo Bio Tech Limited, a member of the promoter group, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 each, including a premium of Rs. 18 per share. The company received approximately Rs. 3.60 crore, representing the remaining 75% of the application money required for the conversion. This transaction increases the company's total paid-up equity capital to Rs. 105.41 crore.
Key Highlights
Allotment of 17,14,285 equity shares of Rs. 10 each at a premium of Rs. 18 per share
Receipt of Rs. 3,59,99,985 as the final 75% payment for warrant conversion
Shares allotted to Vivo Bio Tech Limited, part of the Promoter Group
Total paid-up share capital increased to 10,54,11,181 equity shares
💼 Action for Investors
The conversion of warrants by a promoter group entity indicates long-term commitment and confidence in the company's valuation. Investors should monitor how the fresh capital infusion is utilized for business expansion or debt reduction.
Virinchi Allots 10.5 Lakh Equity Shares Following Warrant Conversion
Virinchi Limited has successfully allotted 1,050,000 equity shares of Rs. 10 each following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 25 per share, which includes a premium of Rs. 15. The company received the remaining 75% of the application money, amounting to approximately Rs. 1.97 crore, from a public category investor. This conversion has increased the company's total paid-up share capital to approximately Rs. 103.70 crore.
Key Highlights
Allotment of 10,50,000 equity shares to Manumon Chettiar under the public category
Issue price fixed at Rs. 25 per share, including a premium of Rs. 15 per share
Receipt of Rs. 1,96,87,500 representing the 75% balance payment for the warrant conversion
Total subscribed share capital increased to 10,36,96,896 equity shares
💼 Action for Investors
Investors should view this as a positive capital infusion that strengthens the balance sheet, despite the marginal equity dilution. Monitor how the company utilizes these funds for its healthcare or IT business segments.
Virinchi to Raise ₹7.83 Cr via Warrant Issue to Promoter in Healthcare Subsidiary
Virinchi Limited is seeking shareholder approval to issue 52.22 lakh convertible equity warrants in its wholly-owned subsidiary, Virinchi Health Care Private Limited, to the company's promoter, Mr. Viswanath Kompella. The warrants are priced at ₹15 each, valuing the healthcare subsidiary at an enterprise value of ₹312.08 crore. Upon conversion, the promoter's stake in the subsidiary will rise to a maximum of 49%, while Virinchi Limited will retain a controlling 51% stake. This move aims to infuse capital into the healthcare arm while maintaining management control by the parent company.
Key Highlights
Issue of 52,22,000 convertible warrants in Virinchi Health Care Private Limited to Promoter Viswanath Kompella.
Warrants priced at ₹15 per unit, aggregating to a total investment of approximately ₹7.83 crore.
Healthcare subsidiary valued at an enterprise valuation of ₹312.08 crore by an IBBI-registered valuer.
Parent company Virinchi Limited to reduce stake from 100% to a minimum of 51% post-conversion.
Warrants are convertible within 36 months with 25% of the price payable upfront.
💼 Action for Investors
Investors should evaluate the fairness of the ₹312.08 crore valuation for the healthcare subsidiary and the impact of the parent company's diluted ownership. While the promoter's capital infusion is a sign of commitment, the transition from a 100% subsidiary to a 51% joint-controlled entity is a significant structural change.
Virinchi Promoter to Invest in Subsidiary via 52.22 Lakh Warrants at Rs 15 Each
Virinchi Limited's board has approved a proposal for its promoter, Mr. Viswanath Kompella, to invest in its material subsidiary, Virinchi Health Care Private Limited. The investment involves the issuance of 52,22,000 convertible equity warrants at a price of Rs. 15 per warrant, based on an enterprise valuation of Rs. 312.08 crore for the subsidiary. This transaction will result in the promoter holding up to 49% of the subsidiary's post-issue equity capital. The capital infusion is intended to improve liquidity and strengthen the subsidiary's balance sheet for long-term growth.
Key Highlights
Promoter Mr. Viswanath Kompella to acquire up to 49% stake in material subsidiary Virinchi Health Care
Issuance of 52,22,000 convertible equity warrants at Rs. 15 per warrant (FV Rs. 10 + Premium Rs. 5)
Subsidiary enterprise valuation pegged at Rs. 312.08 crore by an independent valuer
Warrants have a conversion tenure of 36 months from the date of allotment
Investment aimed at improving liquidity and strengthening the subsidiary's balance sheet
💼 Action for Investors
Investors should view the promoter's direct capital infusion as a sign of confidence in the healthcare vertical, though they should monitor the impact of equity dilution in the subsidiary on consolidated earnings.
Virinchi Allots 74 Lakh Convertible Warrants to Promoter Group at Rs 28 Per Share
Virinchi Limited has approved the allotment of 74,00,000 convertible equity warrants to Vivo Bio Tech Limited, a promoter group entity. The warrants are issued at Rs 28 each, with the company receiving 25% (Rs 5.18 crore) upfront and the remaining 75% due upon conversion within 18 months. This move is expected to increase the promoter group's stake from 37.51% to 41.71% upon full conversion of this tranche. The funds will likely support the company's capital requirements or growth initiatives.
Key Highlights
74,00,000 warrants allotted to promoter group entity Vivo Bio Tech Limited at Rs 28 per warrant.
Immediate cash inflow of Rs 5.18 crore representing 25% of the total issue price.
Promoter group shareholding projected to rise to 41.71% from 37.51% after conversion.
Warrants are convertible into equity shares on a 1:1 basis within a maximum period of 18 months.
💼 Action for Investors
The promoter's decision to increase their stake at a fixed price indicates long-term commitment and confidence. Investors should monitor the company's upcoming quarterly results to see if the capital infusion translates into improved operational performance.
Virinchi Ltd Allots 86 Lakh Convertible Warrants to Promoter Group at Rs 28 Per Share
Virinchi Limited has approved the allotment of 86,00,000 convertible equity warrants to Vivo Bio Tech Limited, a promoter group entity. The warrants are issued at a price of Rs. 28 each, with the company receiving 25% (Rs. 6.02 crore) of the total consideration upfront. The remaining 75% is payable within 18 months upon conversion into equity shares. This move is expected to increase the promoter group's stake from 37.51% to 42.34% on a fully diluted basis, indicating strong internal confidence.
Key Highlights
Allotment of 86,00,000 convertible warrants to promoter group entity Vivo Bio Tech Limited
Issue price set at Rs. 28 per warrant, including a premium of Rs. 18
Immediate capital infusion of Rs. 6.02 crore representing 25% of the total subscription amount
Promoter holding projected to increase from 37.51% to 42.34% upon full conversion
Warrants are convertible into equity shares within a maximum period of 18 months
💼 Action for Investors
Investors should note the promoter group's increased stake as a sign of long-term commitment and confidence in the company's valuation. Monitor the conversion of the remaining warrants and the deployment of the raised capital into growth initiatives.
Virinchi Ltd Allots 40 Lakh Convertible Warrants at Rs 28 Per Unit
Virinchi Limited has approved the allotment of 40,00,000 convertible equity warrants to IT Peer Technologies LLC on a preferential basis. The warrants are issued at a price of Rs. 28 per unit, with the company receiving 25% (Rs. 2.80 crore) of the total consideration upfront. The remaining 75% (Rs. 21 per warrant) is payable within 18 months for conversion into equity shares. This allotment is part of a larger shareholder-approved plan to issue up to 2 crore warrants.
Key Highlights
Allotment of 40,00,000 convertible warrants at an issue price of Rs. 28 (Face Value Rs. 10 + Premium Rs. 18)
Immediate capital infusion of Rs. 2.80 crore representing 25% of the total subscription amount
Warrants are convertible into equity shares on a 1:1 basis within a maximum period of 18 months
Allottee IT Peer Technologies LLC belongs to the Public category, increasing public shareholding post-conversion
Total equity base to expand from 10.26 crore to 10.66 crore shares upon full conversion of these warrants
💼 Action for Investors
Investors should track the utilization of the raised capital for growth initiatives and note the potential equity dilution of approximately 3.7% from this specific allotment. The issue price of Rs. 28 provides a floor valuation reference for the stock over the medium term.